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Abstract Kinetic constants of human class IV alcohol dehy-
drogenase (cc-ADH) support a role of the enzyme in retinoid
metabolism, fatty acid g-oxidation, and elimination of cytotoxic
aldehydes produced by lipid peroxidation. Class IV is the human
ADH form most efficient in the reduction of 4-hydroxynonenal
(kcat/Km : 39 500 mM31 min31). Class IV shows high activity
with all-trans-retinol and 9-cis-retinol, while 13-cis-retinol is not
a substrate but an inhibitor. Both all-trans-retinoic and 13-cis-
retinoic acids are potent competitive inhibitors of retinol
oxidation (Ki : 3^10 WM) which can be a basis for the regulation
of the retinoic acid generation and of the pharmacological
actions of the 13-cis-isomer. The inhibition of class IV retinol
oxidation by ethanol (Ki : 6^10 mM) may be the origin of toxic
and teratogenic effects of ethanol. H2-receptor antagonists are
poor inhibitors of human and rat classes I and IV (Kis 0.3 mM)
suggesting a small interference in ethanol metabolism at the
pharmacological doses of these common drugs.
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1. Introduction
An increasing amount of evidence supports that alcohol
dehydrogenase (ADH, EC 1.1.1.1) in vertebrates performs
speci¢c metabolic functions in the interconversion of alcohols
and aldehydes of particular structures, besides the better
known role in alcohol detoxi¢cation. The most important
pieces of evidence are: the multiplicity of structurally di¡erent
ADH forms, grouped into classes, that coexist in the same
species [1,2] ; the distinct kinetic properties of each class
[1,3^5]; the characteristic distribution of each class in organs
and tissues [6,7] ; and the early expression during embryonic
development [8].
In the present work we investigate some functional charac-
teristics of human class IV ADH or cc-ADH. This is a spe-
cially interesting ADH because of its distribution in various
epithelial tissues such as upper digestive tract mucosa and
cornea, but not in liver [6]. Moreover, class IV exhibits high
activity with retinoids [4,9] and the expression of mouse class
IV in tissues coincides spatiotemporally with the generation of
retinoic acid [8,10], which supports a role of the enzyme as a
retinol dehydrogenase in the crucial pathway of retinoic acid
formation. In the present work we study the kinetics of hu-
man class IV ADH with retinoids of physiological relevance,
and the inhibition of retinol oxidation by other retinoids (of
interest to understand a possible mechanism of regulation)
and by ethanol (a possible origin of ethanol toxicity and ter-
atogenesis). In addition we have explored the activity of class
IV with other endogenous compounds, putative physiological
substrates of class IV, such as g-hydroxyfatty acids and cyto-
toxic aldehydes derived from lipid peroxidation. These have
been shown to be good substrates for rat class IV ADH [4],
but the rat and the human class IV enzymes, although strictly
homologous (88% sequence identity), exhibit striking kinetic
di¡erences [5], which makes it necessary to separately inves-
tigate the human class IV properties. Finally we report the
e¡ect of H2-receptor antagonists, commonly prescribed drugs
for peptic ulcer, on the activity of the human and rat alcohol
dehydrogenases.
2. Materials and methods
2.1. Materials
NAD, NADH, g-hydroxyfatty acids, retinoids, DEAE-Sepharose
and AMP-Sepharose were from Sigma. 2-Hexenol and 2-hexenal were
from Aldrich. 4-Hydroxynonenal was provided by Prof. H. Ester-
bauer, University of Graz (Graz, Austria). Preparation of the alkenal
was performed as previously indicated [4]. Other alcohols and
aldehydes were from Merck. Cimetidine, ranitidine and famotidine
were from Uquifa (Barcelona).
2.2. Enzyme preparation
Human class IV ADH was prepared from gastric tissue according
to a previously published procedure [11]. From the corresponding
DEAE-Sepharose chromatography step of the class IV puri¢cation
[11], class I QQ-ADH isozymes were isolated and ¢nally puri¢ed on
an AMP-Sepharose column equilibrated in 200 mM Tris-HCl, 0.5
mM dithiothreitol, pH 8.2, and eluted by a linear gradient of 0^0.4
mM NADH. Recombinant human class IV ADH was puri¢ed from
Escherichia coli cells (Allali-Hassani et al., unpublished results). Rat
(Sprague-Dawley) class I was puri¢ed from liver as reported [3], but
using AMP-Sepharose instead of CapGapp-Sepharose for the last
puri¢cation step. Rat class IV was prepared from stomach according
to [12].
2.3. Enzymatic activity
Activity was determined spectrophotometrically by monitoring the
change in absorbance at 340 nm, with a Varian Cary 219 instrument,
at 25‡C, using an O340 for NADH of 6220 M31 cm31. Activity was
measured in 0.1 M glycine/NaOH, pH 10.0, or in 0.1 M sodium
phosphate, pH 7.5. Alcohol oxidation was measured at pH 10.0 or
7.5, with 2.4 mM NAD or 4 mM NAD (rat class IV), while aldehyde
reduction was performed at pH 7.5 with 1.33 mM NADH in a 0.2 cm
light-path cell. Activity with retinoids was determined as previously
indicated [4,13]. 9-cis-Retinol was synthesized by reduction of 9-cis-
retinal with sodium borohydride [14] and the purity con¢rmed by
HPLC. The O326 calculated for 9-cis-retinol was 39 733 M31 cm31 in
0.1 M sodium phosphate, pH 7.5, 0.02% Tween 80. Kinetic constants
were calculated by using the non-linear regression program Enz¢tter
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(Elsevier Biosoft). Inhibition of retinol oxidation by ethanol and other
retinoids was analyzed with the COMP program [15].
Inhibition of ethanol oxidation by H2-receptor antagonists (cimeti-
dine, ranitidine and famotidine) was measured at pH 7.5 or 10.0,
using concentrations up to 2 mM inhibitor. Inhibition kinetics by
ranitidine was measured at 360 nm, since this drug absorbs at 340
nm, using an O360 for NADH of 4200 M31 cm31. Ki was determined
from the secondary representation of the Lineweaver-Burk plots.
3. Results and discussion
3.1. Physiological substrates
3.1.1. g-Hydroxyfatty acids. Table 1 shows the kinetic
constants of human class IV ADH with di¡erent compounds
of physiological interest. Medium- and long-chain g-hydrox-
yfatty acids are good substrates for the enzyme, with kcat/Km
values increasing as the chain length increases. Kinetics with
16-hydroxy-hexadecanoic acid could not be performed at pH
7.5 because of its low solubility at this pH.
The g-oxidation of fatty acids has been reported in many
tissues, and although it is a minor pathway in normal con-
ditions, it increases in abnormal states such as diabetes or
starvation, and by ethanol consumption [16,17]. The oxida-
tion is initiated by the g-hydroxylase activity of several mem-
bers of the cytochrome P-450 family and the resulting g-hy-
droxyfatty acids are further oxidized to dicarboxylic acids by
alcohol and aldehyde dehydrogenases [18]. The kinetic con-
stants with g-hydroxyfatty acids (Table 1) suggest that human
class IV plays a role in this pathway, mostly in the oxidation
of long-chain compounds.
3.1.2. Cytotoxic aldehydes. Aldehydes known to be prod-
ucts of lipid peroxidation, and some of the corresponding
alcohols were also analyzed (Table 1). All compounds are
e⁄ciently transformed by class IV, hexanal being the best
substrate because of a very high kcat. The relative kcat values
for alcohols and aldehydes of this group of substrates agree
with early observations that the 2,3 unsaturation favors the
oxidative direction of the ADH-catalyzed reaction [19].
Kinetic constants suggest that human class IV ADH is ef-
fective in the removal of cytotoxic aldehydes produced by
lipid peroxidation. It has been previously demonstrated that
several human class I ADH isozymes and class II ADH are
also e⁄cient in the reduction of 4-hydroxyalkenals [20], class
II (ZZ-ADH) being the most active, with a kcat/Km for 4-hy-
droxynonenal of 28 000 mM31 min31. The value for class IV
is even higher (39 500 mM31 min31), indicating that class IV
ADH is the most e¡ective human ADH in the reductive elim-
ination of 4-hydroxynonenal. The same conclusion was
reached for the rat species where class IV was the best
ADH in the reduction of 4-hydroxynonenal and of all other
cytotoxic aldehydes tested [4]. ADH, aldehyde dehydrogenase
and glutathione S-transferase are involved in the metabolic
elimination of 4-hydroxynonenal. The contribution of class I
ADH has been estimated to be about 10% of the total 4-
hydroxynonenal metabolism in rat hepatocytes [21,22]. How-
ever, the contribution of the ADH reductive pathway in epi-
thelia may be higher than in the hepatic cells because of the
presence of class IV, the most active ADH form, in these
tissues. Class IV in epithelia may constitute a metabolic pro-
tection against cytotoxic aldehydes in areas of active lipid
peroxidation.
3.1.3. Retinoids. The kinetic experiments with retinoids
were performed with a recombinant enzyme (Table 2),
although the constants found are indistinguishable from those
obtained with the gastric class IV (results not shown). Except
for 13-cis-retinol and 13-cis-retinal, which are not substrates,
the all-trans and 9-cis isomers of retinol and retinal are e¡ec-
tively transformed by human class IV ADH. The enzyme ex-
hibits the highest catalytic e⁄ciency with 9-cis-retinol. Inter-
estingly, in terms of kcat/Km, alcohols are better substrates
than the corresponding aldehydes, supporting a physiological
role for class IV in retinol oxidation, in the crucial pathway
for retinoic acid generation. Kinetic constants for the all-
trans-retinoids and 9-cis-retinal are similar to those previously
reported [9]. For these three substrates, class IV ADH is the
most active retinol dehydrogenase form of human ADH [9].
No data are available on the kinetics of 9-cis-retinol with the
human class I and class II enzymes. Interestingly, several class
I isozymes and class II ADH are active with 13-cis-retinal [9],
but we have not found any activity for class IV with either 13-
cis-retinol nor 13-cis-retinal, in a concentration range of 7^150
WM (Table 2). Thus, while all-trans-retinol ¢ts better in the
class IV active site than in the class I site [23,24], this seems
not to be the case for the 13-cis-isomer.
Ethanol inhibits both all-trans-retinol and 9-cis-retinol oxi-
dation by class IV ADH (Table 3) with Ki values (6^10 mM)
in the range of the blood ethanol concentrations after social
drinking. This supports the notion that alcohol consumption
interferes with the normal metabolism of retinoids and that
this could be one of the mechanisms of the toxic and terato-
genic e¡ects of ethanol [25].
The relative contribution of ADH (classes I, II and IV) and
that of the more speci¢c microsomal retinol dehydrogenases
in the retinol-retinal interconversion is controversial [26]. The
great amount of ADH in liver (classes I and II) makes the
isozymes of these classes suitable for the oxidative elimination
of excess of retinol in the organism, which is supported by the
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Table 1
Kinetic constants of human class IV ADH with g-hydroxyfatty acids and products of lipid peroxidation
Substrate Km (mM) kcat (min31) kcat/Km (mM31 min31)
10-OH-Decanoic acid 0.1 59 590
12-OH-Dodecanoic acid 0.17 (0.07) 660 (2 150) 3 880 (30 750)
16-OH-Hexadecanoic acid (0.035) (1 320) (37 715)
Hexanol 0.14 900 6 430
Hexanal 0.02 27 230 1 361 700
2-Hexenol 0.017 3 130 184 100
2-Hexenal 0.025 2 930 117 200
4-Hydroxynonenal 0.038 1 510 39 500
The enzyme was puri¢ed from stomach. Activities were determined in 0.1 M sodium phosphate, pH 7.5. In parentheses, activities with 0.1 M
glycine/NaOH, pH 10.0.
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inhibition of the process by 4-methylpyrazole [27]. Class IV
ADH, which is present in many epithelial tissues but not in
liver [6,11] and exhibits high Km values for short-chain alco-
hols, seems suitable for a more speci¢c role in cellular retinoid
metabolism. There is evidence in favor of microsomal retinol
dehydrogenase as a main enzyme in retinol oxidation for ret-
inoic acid generation, such as the recognition of CRBP-retinol
as substrate, its speci¢city towards retinol and its low Km [28].
However, activity of ADH with CRBP-retinol has not been
investigated, while, regarding speci¢city, retinol dehydrogen-
ases also use hydroxysteroids [29,30]. Finally, although Km for
retinoids is higher for ADH, class IV exhibits a high kcat/Km
ratio (Table 2), which is the best measure of the enzyme con-
tribution at low substrate concentration. This value is not
available for retinol dehydrogenase because a pure prepara-
tion has not been obtained [31]. Two recent results support
the involvement of class IV in retinol metabolism. (1) It has
been demonstrated that the initial detection of retinoic acid
during mouse embryogenesis (day 6.5) coincides spatiotem-
porally with co-expression of class IV ADH and class 1
ALDH (an aldehyde dehydrogenase that oxidizes retinal to
retinoic acid) [8]. (2) A class IV-like ADH is present in am-
phibians indicating a general occurrence of the enzyme in
vertebrates, that could be related to the general need for ret-
inoid signalling in these animals [32].
The oxidation of retinol to retinal is probably the limiting
step in the generation of retinoic acid [26,28] ; it is therefore of
extreme interest to elucidate the role of the enzymes involved
in the process, the mechanism of exposing retinol to the active
site of the dehydrogenase from the CRBP-retinol complex and
the regulation of the system. The importance of this step may
explain the need of a certain degree of redundancy, provided
by the existence of several enzymatic systems active with ret-
inol: the cytosolic ADH (classes I, II and IV), the microsomal
retinol dehydrogenase (three types) [28], and several types of
cytosolic retinol dehydrogenase [33,34]. Contributions of each
enzymatic system may di¡er among tissues. Thus blood vessel
endothelium, a tissue with probable requirement for retinoic
acid, does not contain microsomal retinol dehydrogenase [35]
but it exhibits high ADH activity (class I in humans and class
IV in rat) [7].
9-cis-Retinoic acid is the only retinoid that interacts with
the retinoid X receptor. Its pathway of formation is not clear,
although several possibilities have been discussed: dietary ori-
gin, cleavage of 9-cis-carotenoids, isomerization at the level of
all-trans-retinoic acid, or isomerization at the level of all-
trans-retinol and further oxidation to the acid form [36].
The presence of endogenous 9-cis-retinol [37], the high activity
of class IV ADH with 9-cis-retinol (Table 2), the recent report
of short-chain dehydrogenases active with 9-cis-retinol [30,36]
and the existence of aldehyde dehydrogenases active with 9-
cis-retinal [28,37] support the last possibility.
13-cis-Retinol is not a substrate of class IV but it is an
e¡ective competitive inhibitor of the oxidation of 9-cis-retinol
(Table 3). This suggests that it binds strongly to the enzyme,
like the all-trans and 9-cis isomers, but unproductively be-
cause the cis con¢guration in the close proximity of the alco-
hol group may impair the correct positioning of this reactive
group in the active site. Interestingly, other retinoid-associated
proteins discriminate against 13-cis-isomers [28].
All-trans-retinoic acid is a powerful inhibitor of the class IV
retinol dehydrogenase activity (Table 3). Although the Ki val-
ue is high (10 WM) in comparison to the cellular retinoic acid
concentrations (0.03^0.2 WM in mouse embryo [38,39]), it may
be of physiological signi¢cance at the local concentrations in
places of active retinoic acid synthesis. The inhibition of the
¢rst step by the end product of the pathway may represent a
regulatory mechanism of retinoic acid homeostasis.
Also of interest is the potent inhibition of retinol oxidation
by 13-cis-retinoic acid (Ki 3 WM). The 13-cis-retinoic acid is
being used in the treatment of dermatological diseases and
some forms of cancer, with pharmacological concentrations
reaching in blood up to 7 WM [40]. It has been proposed
that its actions, both bene¢cial and highly teratogenic in
some conditions, could be related to a higher stability and
to a slow isomerization to all-trans-retinoic acid, the active
compound, since the 13-cis-isomer does not bind the nuclear
receptors [41]. However, in contradiction with this hypothesis,
treatment of experimental animals with high doses of 13-cis-
retinoic acid does not result in an increase of all-trans-retinoic
acid concentration [42]. The demonstration that 13-cis-retinoic
acid is a powerful inhibitor of all-trans-retinol oxidation by
class IV ADH (Table 3) and, therefore, an inhibitor of the all-
trans-retinoic acid synthesis, provides an alternative mecha-
nism for the pharmacological actions of this widely used ret-
inoid.
FEBS 20141 27-4-98
Table 3
Inhibition of human class IV retinol dehydrogenase activity
Substrate Inhibitor Ki (mM)
all-trans-Retinol ethanol 6
9 (37‡C)
9-cis-Retinol ethanol 10
9-cis-Retinol 13-cis-retinol 0.013
all-trans-Retinol 13-cis-retinoic acid 0.003
all-trans-Retinol all-trans-retinoic acid 0.010
Activities were determined at pH 7.5 and 25‡C (except where indicated) using the recombinant enzyme. All inhibitions showed a competitive
pattern.
Table 2
Kinetic constants of human class IV ADH with retinol and retinal
isomers
Substrate Km (WM) kcat (min31) kcat/Km (mM31 min31)
all-trans-Retinol 15 þ 4 67 þ 10 4 500 þ 1 370
9-cis-Retinol 36 þ 4 475 þ 44 13 300 þ 2 020
13-cis-Retinol N.A.
all-trans-Retinal 34 þ 6 110 þ 25 3 300 þ 960
9-cis-Retinal 21 þ 5 190 þ 24 8 980 þ 2 350
13-cis-Retinal N.A.
The enzyme was obtained by expression of its cDNA in E. coli. Ac-
tivities were determined in 0.1 M sodium phosphate, pH 7.5, 0.02%
Tween 80. Results are expressed as the mean þ S.E.M. of least three
determinations. N.A.: no activity.
A. Allali-Hassani et al./FEBS Letters 426 (1998) 362^366364
The capacity of several retinoids to modulate the retinol
oxidation activity of class IV ADH further sustains the phys-
iological implication of the enzyme in retinoid metabolism.
3.2. Inhibition by H2ÿreceptor antagonists
H2-receptor antagonists, common drugs for the treatment
of peptic ulcer, were used as inhibitors of ethanol oxidation
(Table 4). Cimetidine, ranitidine and famotidine a¡ected
very di¡erently the human class I (QQ-ADH) and class
IV ADH activities. Cimetidine competitively inhibited class
IV, while it did not inhibit class I. In contrast, ranitidine
and famotidine did not a¡ect class IV ADH activity but in-
hibited class I. These results resemble only partially those of a
previous report [43], although some of the discrepancies could
be due to di¡erences in the substrate or assay temperature
used.
Regarding the rat enzyme, cimetidine and ranitidine inhib-
ited the class IV enzyme, but none of the studied compounds
inhibited class I. In contrast, a previous report [44], using
stomach and liver crude homogenates, found inhibition of
both class I and class IV by either of the antagonists, although
in some cases with high Ki values. From the present and
previous works on both species, it can be concluded that
cimetidine inhibits ethanol oxidation with a competitive pat-
tern, class IV being more strongly inhibited than class I, while
inhibition by other H2-antagonists shows a more complex
pattern, and has more e¡ect on class I than on class IV. These
results support signi¢cant structural di¡erences between class
I and class IV active sites [23,24,45]. In all cases the Ki values
are higher than 0.3 mM, well above the pharmacological con-
centrations of these compounds (0.2^11.2 WM, [44]), suggest-
ing that the usual treatment with the H2-receptor antagonists
studied will have little e¡ect on alcohol metabolism. It has
been argued that these drugs can accumulate in gastric cells
after an oral dose [44] but, even if this is the case, a partial
inhibition of gastric ADH will not practically have any e¡ect
because of the small contribution of the stomach to overall
ethanol metabolism [11,46,47].
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